Elite Pharmaceuticals, Inc.
ELTP
$0.37
$0.00-0.62%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 28.99% | -13.03% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 28.99% | -13.03% | |||
| Cost of Revenue | 7.19% | -16.24% | |||
| Gross Profit | 60.36% | -7.96% | |||
| SG&A Expenses | 207.65% | -38.43% | |||
| Depreciation & Amortization | -4.66% | -1.72% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 31.62% | -19.68% | |||
| Operating Income | 22.42% | 9.73% | |||
| Income Before Tax | 0.10% | 32.78% | |||
| Income Tax Expenses | 6.85% | 12.68% | |||
| Earnings from Continuing Operations | -0.71% | 35.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.71% | 35.70% | |||
| EBIT | 22.42% | 9.73% | |||
| EBITDA | 21.30% | 9.21% | |||
| EPS Basic | -1.16% | 35.16% | |||
| Normalized Basic EPS | 4.13% | 32.97% | |||
| EPS Diluted | 67.80% | 9.26% | |||
| Normalized Diluted EPS | 0.00% | 32.56% | |||
| Average Basic Shares Outstanding | 0.25% | 0.21% | |||
| Average Diluted Shares Outstanding | 4.21% | -0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||